At Kura Oncology we are committed to realizing the promise of precision medicines for the treatment of cancer. January 11 2021 0205 PM.
Pipeline Kura Oncology
Kura Oncologys lead drug candidate is tipifarnib a farnesyl transferase inhibitor which is currently being studied in multiple Phase 2 clinical trials.
Kura oncology pipeline. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura Oncology a biopharmaceutical company advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers. Tipifarnib will also be evaluated in combination with an inhibitor of PI3Kalpha to treat between 20-50 of patients with HNSCC.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kuras pipeline consists of Tipifarnib and KO-539. The Investor Relations website contains information about Kura Oncology Incs business for stockholders potential investors and financial analysts.
The Companys pipeline consists of small. Tipifarnib is a farnesyl transferase inhibitor that recently received Breakthrough Therapy Designation BTD for the treatment of patients with certain head and neck cancers that carry HRAS mutations. We now understand that a patients response to treatment depends in part on the cancers genetic makeup.
Kura Oncologys diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology is a biopharmaceutical company that has joined the genetic revolution. Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb Kura Oncology Myriad Genetics and Merck to Advance Comprehensive Genomic Profiling.
About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The preclinical pipeline includes KO-947 an ERK inhibitor and a menin-MLL program. Kura Oncology also has an investigational treatment for leukemia in its pipeline KO-539 which works the same way SNDX-5613 does by blocking the interaction between.
Kuras product pipeline includes two small molecule drugs that target cancers signaling pathways. The company has two assets in human trials with its lead candidate. This new era of precision medicine offers the potential for innovative treatments that.
The genomics revolution is transforming how we treat cancer. The Companys pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve. Kura Oncology does not guarantee the accuracy or completeness of this information and is not liable for any delays inaccuracies errors in or omissions of any such information or for any actions taken in reliance on this information or for any damages arising therefrom.
Kura Oncologys diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The companys diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura realizes that a patients response to treatment depends on his or her cancers genetic identity.
Kura Oncology KURA is a San Diego-based clinical-stage biopharmaceutical concern focused on the treatment of cancer. Kura Oncologys approach to drug development is focused on rapidly translating novel science into life-saving medicines. About Kura Oncology.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Download this Press Release PDF Format opens in new window SAN DIEGO--BUSINESS WIRE-- With genetic sequencing at the forefront of. Additionally Kuras pipeline carries KO-539 an inhibitor of menin.
